Searchable abstracts of presentations at key conferences in endocrinology

ea0029p132 | Bone & Osteoporosis | ICEECE2012

Osteoporosis and vitamin D deficiency in patients with lipid storage disease

Del Prete M. , Negri A. , Sarnataro M. , Pivonello C. , Ramundo V. , Marotta V. , Russo R. , Carratu A. , Cianciaruso B. , Colao A. , Pisani A. , Faggiano A.

Introduction: Bone metabolism is impaired in several lipid storage diseases. At now no data are available in Fabry disease (FD), a genetic lipid storage disease characterized by systemic accumulation of glicolipids. The aim of this study was to evaluate bone metabolism and calcium/vitamin-D pathway in patients with FD.Methods/design: Study population included 15 FD patients (8 M and 7 F, age 28–59 years) and 15 sex-, age- and BMI-matched normal subj...

ea0029p774 | Endocrine tumours and neoplasia | ICEECE2012

Diagnostic and Prognostic Role of 68GA-Dotatate in Patients with Neuroendocrine Tumors

Marciello F. , Faggiano A. , Aloj L. , Caraco C. , Ramundo V. , Marotta V. , Del Prete M. , Carratu A. , Colao A. , La Storia S.

Octreoscan is currently the gold standard for diagnosis of somatostatin receptor positive NET but it is limited by a lower spatial resolution and physiological uptake noises. DOTATATE is a somatostatin analogue, radiolabelled with 68Ga and adapted for PET imaging.Aim of this study was to evaluate the diagnostic performance of 68Ga-DOTATATE PET compared to Octreoscan in NET.Fifty-one patients with NET (40 sporadic, 17 MEN1) of diffe...

ea0029p1787 | Thyroid cancer | ICEECE2012

Simultaneous occurrence of BRAF mutation and RET/PTC rearrangement is frequent in papillary thyroid carcinoma

Guerra A. , Marotta V. , Di Stasi V. , Volpe A. , Murino A. , Di Stasi M. , Vitale M.

Context: Initial studies reported that RET rearrangements, RAS mutations and BRAF mutation are mutually exclusive genetic events in papillary thyroid carcinoma (PTC). Subsequently, simultaneous occurrence of BRAF mutation and RET/PTC or H4-PTEN has been described in few PTC cases, indicating that these genetic alterations might coexist in PTC in the same cell or in different cells, at least sporadically. In light of the recent finding that frequently BRAF mutation is present o...

ea0029p779 | Endocrine tumours and neoplasia | ICEECE2012

Sorafenib stops disease progression in the majority of patients with advanced differentiated thyroid cancer refractory to radioactive iodine.

Marotta V. , Ramundo V. , Del Prete M. , Marciello F. , Palmieri G. , Camera L. , Vitale M. , Colao A. , Faggiano A.

Differentiated thyroid cancers (DTC) have an excellent prognosis with a 10 year disease-related survival of 85%. However, about 5% of DTC patients develop an aggressive disease with distant metastasis and loss of radioactive iodine (RAI) avidity. An effective treatment is not available for these patients and survival rates are less than 15%. The MAP-kinase pathway is strikingly involved in the pathogenesis of DTC. This is why compounds striking the MAP-Kinase pathway may be us...

ea0029p807 | Endocrine tumours and neoplasia | ICEECE2012

Long-acting somatostatin analogues are highly effective in men1 patients with early stage duodeno-pancreatic neuroendocrine tumors

Faggiano A. , Ramundo V. , Del Prete M. , Marotta V. , Marciello F. , Camera L. , Napolitano V. , De L. , Lombardi G. , Colao A.

Somatostatin analogues (SSA) represent a recognized therapeutic option in patients affected with functioning neuroendocrine tumors (NET). In non-functioning NET, SSA are reported to induce tumor stabilization in most of cases and objective response in <5%. NET associated to Multiple Endocrine Neoplasia type 1 (MEN1) are inherited tumors, generally located in the duodeno-pancreatic trait, characterized by well differentiated histotype, high expression of somatostatin recept...

ea0029p1124 | Neuroendocrinology | ICEECE2012

Autoimmune thyroid disease and neuroendocrine gastric tumors: early detection and efficacy of somatostatin analogue treatment

Accardo G. , Renzullo A. , De Bellis A. , Bizzarro A. , Romano M. , Federico A. , Gravina A. , Faggiano A. , Marotta V. , Esposito D. , Bellastella A. , Pasquali D.

Autoimmune chronic thyroid disease (AITD) is associated with atrophic gastritis (CAG) in 29–42% of the cases. CAG and the consequent hypergastrinemia, listed as precancerous lesion, can predispose to neuroendocrine cells hyperplasia and the development of neuroendocrine gastric tumors (NET). Aim of this study was to evaluate the association of AITD with risk of gastric NET and the efficacy of somatostatin analogues treatment.Patients: From 2009 to 2...

ea0029p1797 | Thyroid cancer | ICEECE2012

Papillary thyroid carcinoma with high percentage of BRAFV600E alleles have a higher recurrence rate

Guerra A. , Fugazzola L. , Marotta V. , Cirillo M. , Di Stasi V. , Volpe A. , Murino A. , Di Stasi M. , Vitale M.

Context: Although unexplained conflicting results are present in the literature, most of studies report the association of BRAFV600E in papillary thyroid carcinoma (PTC) with a more advanced disease and with a worst prognosis. We recently demonstrated that in most of the cases PTC consists of a mixture of tumour cells with wild-type and mutant BRAF. Hence, we examined the association of percentage of BRAFV600E alleles with clinicopathologic parameters at diagnosis and disease ...

ea0029p1575 | Thyroid (non-cancer) | ICEECE2012

Thyroid nodules treated with percutaneous radiofrequency thermal ablation: a comparative study

Ramundo V. , Fonderico F. , Assanti A. , Marciello F. , Prete M. Del , Marotta V. , Lombardi G. , Misso C. , Marzano L. , Colao A. , Spiezia S. , Faggiano A.

Introduction: Percutaneous radiofrequency thermal ablation (RTA) is a new promising therapeutic approach to manage compressive thyroid nodules (TNs).Aim: To investigate effectiveness and safety of RTA in the treatment of compressive TNs in patients not receiving surgery or radioiodine.Study design: Forty patients (31–86 years) with compressive TNs were enrolled. Twenty-two patients had non-toxic TNs and 18 had toxic TNs and we...